Nausea
MildClinical (low-high)15%–40%
User-reported45%
Onset1-3 days after starting or dose increase
Eat smaller meals, avoid fatty food, stay hydrated. Take the injection in the evening so you sleep through the worst.
See in predictorThe GLP-1 Safety Database
The world's most comprehensive, transparent collection of GLP-1 and anti-obesity medication safety data. Continuously updated from clinical trials, regulatory reports, and real-world patient experiences.
717
Data Points
15
Effects Tracked
8
Data Sources
1 May 2026
Last Updated
Tracked Effects
Each effect is tracked with clinical and user-reported rates, severity, and management guidance.
Diarrhoea
MildClinical (low-high)10%–25%
User-reported30%
Onset2-5 days after starting
Stay very hydrated. Avoid dairy and high-fibre foods initially. If it persists beyond 3 weeks, contact your doctor.
See in predictorConstipation
MildClinical (low-high)5%–18%
User-reported22%
Onset3-7 days after starting
Increase water intake, add fibre-rich foods gradually, consider a mild fibre supplement. Regular movement helps.
See in predictorReduced appetite
MildClinical (low-high)8%–22%
User-reported55%
Onset3-7 days after starting
Make sure you still eat enough protein (at least 60g/day) to prevent muscle loss. Set reminders to eat if needed.
See in predictorHeadache
MildClinical (low-high)8%–14%
User-reported18%
Onset1-3 days after starting
Stay hydrated — dehydration from reduced food intake is often the real cause. Regular paracetamol is safe to take.
See in predictorPancreatitis (rare)
SevereClinical (low-high)1%–1%
User-reported1%
OnsetCan occur at any point during treatment
If you experience severe stomach pain radiating to your back: STOP the medication immediately and go to the emergency room. Do not wait.
See in predictorFatigue / Low energy
MildClinical (low-high)6%–14%
User-reported25%
Onset5-10 days after starting
Ensure you're eating enough protein and calories — fatigue often means you're eating too little. Light exercise actually helps more than resting.
See in predictorVomiting
ModerateClinical (low-high)3%–8%
User-reported20%
Onset1-3 days after starting or dose increase
Eat very small portions slowly. Avoid lying down after eating. If vomiting is persistent or severe, contact your doctor — dose reduction may help.
See in predictorAbdominal pain
ModerateClinical (low-high)3%–7%
User-reported18%
Onset2-7 days after starting or dose increase
Eat smaller meals, avoid spicy and fatty foods. If pain is severe, persistent, or radiates to the back, see a doctor immediately to rule out pancreatitis.
See in predictorAcid reflux (GERD)
MildClinical (low-high)3%–8%
User-reported20%
Onset3-7 days after starting
Avoid eating 3+ hours before bed. Sleep with your head slightly elevated. Avoid trigger foods (coffee, alcohol, citrus, tomatoes). An OTC antacid can help.
See in predictorGallstones (cholelithiasis)
SevereClinical (low-high)1%–3%
User-reported4%
OnsetTypically months into treatment, correlates with significant weight loss
If you experience sudden sharp pain in the upper right abdomen, especially after eating, seek medical attention. Losing weight gradually (not too fast) reduces risk. Stay hydrated.
See in predictorHair loss (thinning)
MildClinical (low-high)1%–3%
User-reported15%
OnsetTypically 2-4 months after starting (delayed onset)
Ensure adequate protein intake (60-80g/day), consider a multivitamin with biotin, iron, and zinc. Hair loss from weight loss is almost always temporary.
See in predictorInjection site reaction
MildClinical (low-high)3%–5%
User-reported12%
OnsetWithin hours of injection
Rotate injection sites (thigh, abdomen, upper arm). Let the pen reach room temperature before injecting. Apply a cold compress if the area is irritated.
See in predictorDizziness
MildClinical (low-high)2%–5%
User-reported14%
Onset2-7 days after starting or dose increase
Drink at least 2 litres of water daily. Stand up slowly. If you take blood pressure medication, ask your doctor to check if your dose needs adjusting.
See in predictorEmotional blunting / Reduced pleasure
ModerateClinical (low-high)2%–5%
User-reported12%
OnsetGradual onset over 2-6 weeks
If you notice reduced enjoyment of activities you used to love, talk to your doctor. Maintaining social connections and physical exercise can help. This effect is still being studied.
See in predictorData Sources
We collect data from 8 source categories, combining clinical, regulatory, and experiential evidence.
PubMed / PMC
Peer-reviewed clinical trials and systematic reviews from the world's largest biomedical literature database.
FDA FAERS
FDA Adverse Event Reporting System. Post-market safety surveillance data from the United States.
ClinicalTrials.gov
Registry of clinical studies. We track active and completed GLP-1 trials for emerging safety signals.
Real-world patient experiences from 13 subreddits including r/Ozempic, r/Mounjaro, r/loseit, and r/Semaglutide.
Google Scholar
Academic publications, conference papers, and preprints covering GLP-1 receptor agonist safety profiles.
Indian Sources
1mg, Express Pharma, and PvPI (Pharmacovigilance Programme of India). Regional safety data for the Indian market.
Health News
Curated health journalism from STAT News, Reuters Health, BMJ, and major medical publications.
Patient Forums
Structured patient experience data from weight management forums, Trustpilot, and community support groups.
For Researchers
Access our data via a simple REST API. Free for academic use.
# Quick start
curl https://magistra.health/api/data?q=overview| Method | Endpoint | Description |
|---|---|---|
| GET | /api/data?q=overview | Returns metadata: total data points, effects tracked, source breakdown, last updated timestamp. |
| GET | /api/data?q=effects | Returns all 15 tracked effects with clinical rates, user-reported rates, severity, and management tips. |
| GET | /api/data?q=effect&id=nausea | Returns detailed data for a single effect: all data points, source attribution, confidence intervals. |
Need bulk access?
Get in touch for full dataset exports, custom queries, or collaboration opportunities.
Methodology
Our data pipeline operates in five stages: (1) automated collection from all 8 source categories, (2) LLM extraction using Claude Haiku for structured data from unstructured text, (3) two-track estimation that separately weighs clinical and community data, (4) random-effects confidence intervals for every estimate, and (5) log-odds patient modifiers that personalise risk based on sex, age, GI history, diabetes status, and dose tier.
Read the full methodologyCite This Database
Use the following citation when referencing our data in publications or research.
Magistra Health. "GLP-1 Safety Database: Comprehensive Side Effect Tracking from Clinical, Regulatory, and Real-World Sources." magistra.health/en/data. Accessed 1 May 2026.
This database is continuously updated. Always include the access date in your citation.